BioMarin’s Q1 2026: A Portfolio Pivot Lifts Revenue Forecast and Signals Bigger Things Ahead

Snapshot: what BioMarin announced

BioMarin posted first-quarter 2026 revenue of $766 million, up year over year, and said it is increasing its full-year 2026 revenue guidance to a range of $3.825 billion to $3.925 billion. The midpoint implies roughly 20% year‑over‑year growth. The release centers on revenue progress and portfolio expansion rather than explicit EPS figures in this filing, leaving investors to weigh earnings per share (EPS) and EPS consensus as new models are tested against the backdrop of expanding product lines.

The company highlights the closing of its acquisition of Amicus Therapeutics and the addition of GALAFOLD and POMBILITI + OPFOLDA to BioMarin’s portfolio as the core drivers behind the refreshed revenue forecast. Management frames this as a deliberate step to accelerate growth into 2026 and beyond, with a focus on Fabry and Pompe disease markets and a broader, faster-growing commercial footprint.

Strategic moves: Amicus integration and portfolio expansion

The press release emphasizes that the Amicus acquisition is complete, enabling BioMarin to leverage a broadened portfolio—most notably with GALAFOLD for Fabry disease and the Pompe disease assets POMBILITI and OPFOLDA. CEO commentary stresses the potential to reach more patients and accelerate near-term and mid-term growth through a larger, more diversified lineup, coupled with ongoing pipeline progress.

In practical terms, the company is signaling that the 2026 revenue forecast is not just a one-off reflation of a quarterly beat but a structured plan tied to a bigger addressable market and a more robust commercial engine. For investors, the question becomes whether higher revenue guidance translates into sustained earnings power, and how much of the improvement comes from portfolio mix versus cost control and synergy realization from the Amicus deal.

Guidance, leverage, and the EPS angle

The raised revenue forecast suggests a constructive view on operating leverage, but the exhibit does not publicly disclose EPS figures at this stage. Traders and analysts will be paying close attention to whether the revenue uplift flows through to EPS and whether the EPS consensus can be met or exceeded as additional cost of integration and amortization unfolds.

In biotech, “earnings surprise” rarely arises from one quarter alone; it comes from a pattern of margin discipline, R&D pacing, and the timing of milestone-driven revenue. BioMarin’s 2026 plan hinges on a combination of commercial rollout of newly added products and the digestion of pipeline catalysts, with analysts likely to revisit EPS estimates in light of the Amicus integration and the full year revenue cadence.

Pipeline momentum: near-term catalysts and milestones

• PALYNZIQ — approved in the U.S. for adolescents 12+ with phenylketonuria; EU timing expected in 2026. This expands access and potential revenue streams in a key metabolic therapy space.
• BMN 351 — early Phase 1/2 data presented at the Muscular Dystrophy Association conference showing dose-dependent increases in dystrophin expression at Week 25 biopsy in 6 mg/kg and 9 mg/kg cohorts, with supportive biomarkers suggesting muscle health improvements.
• Near-term Phase 3 data readouts and ongoing pipeline progress are highlighted as the strategic backbone for longer-term growth and potential reacceleration in 2027 and beyond.

Implications for BioMarin’s peers and the sector

BioMarin’s strategy—an acquisition-driven expansion paired with a raised revenue forecast—puts a spotlight on portfolio strategy in the rare-disease space. If BioMarin can translate this expanded portfolio into sustained margin improvement and deliver on pipeline milestones, peers may recalibrate their own M&A playbooks and guidance to maintain competitive positioning. The sector could see a broader emphasis on integrating specialty-disease assets, leveraging global scale, and prioritizing near-term data readouts that unlock commercial potential.

Bottom line: execution matters as the data stream accelerates

BioMarin is signaling confidence in a multi-year growth trajectory driven by a larger, more diversified product portfolio and a refreshed revenue forecast. For BMRN investors and sector watchers, the key watchpoints are how EPS shapes up in subsequent releases, whether the Amicus integration delivers the anticipated operating leverage, and how quickly the added assets translate into sustainable earnings quality against a backdrop of ongoing pipeline activity.